Risk-benefit analysis and risk minimization of Quinapril: A review

0Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

The purpose of this review is to give the readers an insight about the risks and benefits of 'quinapril', a potent Angiotensin Converting Enzyme Inhibitor (ACEI). Quinapril is a highly effective novel drug indicated for treatment of congestive heart failure and hypertension. Despite of the fact that safety profile is quite well with low incidence of adverse effects, an attempt has been made to minimize the risks and subsequently minimizing the adverse consequences of this competitive inhibitor, thereby increasing the benefits of this enzyme inhibitor in day to day clinical practice. © 2014 Science Publication.

Author supplied keywords

Cite

CITATION STYLE

APA

Sunny, A., Arif Khan, M., Mahesh, D., Chauhan, N. S., Mishra, R., Presila, N., & Samuel, A. (2014). Risk-benefit analysis and risk minimization of Quinapril: A review. American Journal of Pharmacology and Toxicology, 9(1), 68–74. https://doi.org/10.3844/ajptsp.2014.68.74

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free